Connect Biopharma Holdings Ltd (CNTB)
Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.
Address
12265 EL CAMINO REAL, SUITE 350
SAN DIEGO, CA 92130
Founded
2015
Number of Employees
81
Website
http://www.connectbiopharm.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)